Publications:

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.

Nature Communications

Niu, Mengmeng M; Xu, Jing J; Liu, Yang Y; Li, Yuhuang Y; He, Tao T; Ding, Liangping L; He, Yajun Y; Yi, Yong Y; Li, Fengtian F; Guo, Rongtian R; Gao, Ya Y; Li, Rui R; Li, Luping L; Fu, Mengyuan M; Hu, Qingyong Q; Luo, Yangkun Y; Zhang, Chunyan C; Qin, Kewei K; Yi, Jianqiao J; Yu, Shuhan S; Yang, Jian J; Chen, Hu H; Wang, Liang L; Li, Zhonghan Z; Dong, Biao B; Qi, Shiqian S; Ouyang, Liang L; Zhang, Yujun Y; Cao, Yang Y; Xiao, Zhi-Xiong Jim ZJ

Publication Date: 2021-10-11

Variant appearance in text: EGFR: K806A

PubMed Link: 34635651

Variant Present in the following documents:

• Main text
• 41467_2021_26222_MOESM1_ESM.pdf

View BVdb publication page